Thus, pharmacologic (LDE225) or genetic inhibition (shRNA KD) of SMO leads to reduced expression of GLI1, a key target of Hh signaling, in primary CD34+ CP-CML cells and in a murine model of CP-CML. This evidence concerns the gene GLI1 and chronic myelogenous leukemia, BCR-ABL1 positive.